National
Discharged gay troops ready to re-enlist
‘That’s the life I was destined to lead’
Thomas Cook
For Thomas Cook, deciding whether or not to re-enlist in the U.S. military after “Don’t Ask, Don’t Tell” is off the books is a no-brainer.
Cook, a Houston resident who was discharged in 2004 under the anti-gay law, said he “absolutely” plans to rejoin the armed forces on the day that the military’s gay ban is lifted.
“That’s the life I was destined to lead,” Cook said. “I think military service is in my blood and my past experience in the military — I absolutely loved it. I wouldn’t have changed anything about it. I come from a family of military people, and I’m looking forward to going back into the military as soon as I can — Sept. 20.”
Cook, now 29, said he doesn’t intend to enter the same field in the military that he held upon his discharge, nor will he enter the same branch of service. He served in military intelligence in the Army prior to his separation, but Cook said he plans to join the Air Force nursing field to make use of the education he has since received in that area.
On July 22, President Obama, Defense Secretary Leon Panetta and Chairman of the Joint Chief of Staff Adm. Mike Mullen certified that the U.S. military is ready for open service in accordance with the repeal law signed in December, starting the 60-day period for when “Don’t Ask, Don’t Tell” will be a thing of the past on Sept. 20.
Gay service members discharged under “Don’t Ask, Don’t Tell” will be able to re-enter the armed forces from that point forward. Some service members whose separations received media attention said their affinity for military service leaves no doubt in their mind that they’ll re-enter the military as soon as possible.
Cook, who first joined the Army in 2001, said he feels compelled to continue military service even though he was kicked out after he declared his sexual orientation. In 2003, the team leader in Cook’s company said during a training exercise he’d kill anyone in his crew whom he found out was gay. Cook reported the team leader’s remarks to his battalion commander and said the threat alarmed him because he is gay. The confession started Cook’s discharge proceedings, and he was ultimately separated from the Army under “Don’t Ask, Don’t Tell” on Jan. 20, 2004.
Seeking to rejoin the military, Cook was lead plaintiff in Cook v. Gates, a lawsuit challenging “Don’t Ask, Don’t Tell” that was filed by Servicemembers Legal Defense Network. However, the U.S. District Court in Massachusetts and the U.S. First Circuit Court of Appeals upheld the constitutionality of “Don’t Ask, Don’t Tell” in response to the challenge, forcing Cook to wait for legislative repeal before he could re-enter the military.
Cook said he bears no ill-will toward the military even though he was expelled from his position simply for stating his sexual orientation and was unable to reclaim his role through the litigation in which he was lead plaintiff.
“The organization itself has the policy in place, but the people I worked with didn’t necessarily believe in the policy,” Cook said. “I worked with people and the other soldiers that believe the same things I believed, which is anyone and everyone that is eligible to serve and is capable of serving should be allowed.”
Other service members whose discharges received prominent attention also said they intend to rejoin the armed forces after the gay ban is lifted — but aren’t feeling the same need to re-enlist on Sept. 20 as soon as “Don’t Ask, Don’t Tell” is off the books.
Alex Nicholson (Washington Blade file photo by Michael Key)
Alex Nicholson, executive director of Servicemembers United, is planning to re-enter the military as a member of the Reserves and, after obtaining a law degree, pursue a career as a military lawyer in the Judge Advocate General’s Corps.
“It’s still a lifestyle and a set of people that I am comfortable around and I’ve always had an affinity for,” Nicholson said. “It’s hard to explain the phenomenon and the fraternity that it is.”
Like Cook, Nicholson plans to take a different position than his previous role. Nicholson was an Army intelligence officer prior to his separation at the age of 20 under “Don’t Ask, Don’t Tell” in 2002. A fellow service member outed him to his unit after she read a letter he had written in Portuguese to a man he dated before he joined the Army.
After forming Servicemembers United in 2005, Nicholson became active in the discussion with the White House and Congress that led to legislative repeal of “Don’t Ask, Don’t Tell.” Nicholson was also the sole named plaintiff in the lawsuit Log Cabin Republicans v. United States, which led the U.S. Ninth Circuit Court of Appeals to institute an injunction this year barring further discharges under “Don’t Ask, Don’t Tell.”
Despite his plan to rejoin the military, Nicholson, now 30, said he plans to hold off on re-enlisting for about two or three years as he continues his advocacy work because he doesn’t believe being in the military while acting as a watchdog for gay troops is appropriate.
“I just don’t feel like I would be able to continue to do the job that I do by doing that,” Nicholson said. “That’s going to add a whole additional layer of complexity to the political work, or the watchdog work that we do, if I were to do something like that.”
Also planning to re-enlist is Mike Almy, a former Air Force communications officer who was discharged under “Don’t Ask, Don’t Tell” in 2006. He said he wants back in the armed forces because he has an affinity for it.
“It’s what I’ve done for 13 years,” Almy said. “I miss it, the people, the camaraderie, the mission and want to finish my career.”
After a fellow service member read a private e-mail revealing his sexual orientation and reported the information to his commander, Almy was discharged under “Don’t Ask, Don’t Tell.” He never made a public statement that he was gay, but was nonetheless separated.
Almy, 40, received significant attention as a service member discharged under “Don’t Ask, Don’t Tell” after testifying before the Senate Armed Services Committee last year against the military’s gay ban and taking on tough questioning from Sen. John McCain (R-Ariz.).
The best path that Almy said he sees for re-entering the armed forces is the resolution of the lawsuit in which he is lead plaintiff, Almy v. United States. The case, filed by SLDN and pending before the U.S. District Court of Northern California, seeks to reinstate him and other plaintiffs in the armed forces.
The case, Almy said, represents his best chance to return to the Air Force as an officer because of difficulties in the path ahead if he were to re-enlist at a recruiting station.
“It’s very difficult as an officer to go back on active duty, and that has absolutely nothing to do with ‘Don’t Ask, Don’t Tell,’ but just the fact that being separated and out for a couple years — coupled with the fact that there’s a drawdown — so that’s why we got the lawsuit in the works,” Almy said.
Mike Almy (Washington Blade file photo by Michael Key)
Almy added he’s expecting a resolution to the lawsuit in a couple of months and not the exact same position he held upon discharge, but a position that is comparable and the same rank.
Upon his discharge under “Don’t Ask, Don’t Tell,” Almy lost all the benefits he would have had if he had been allowed to retire on his own accord. His reinstatement in the armed forces would enable him to reclaim those benefits.
“I have none whatsoever,” Almy said. “That’s what we’re trying to get as well. Assuming we’re successful in the lawsuit and win, and get reinstatement, then we’ll pick up where we left off basically, so I’ll get those benefits, go on to finish my career and ultimately retire.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Using movement to boost your mental health during holidays
